

eGFR-C Newsletter

#19 December 2018

www.birmingham.ac.uk/eGFR-C




Message from the Chief Investigator: Dr Edmund Lamb

Thank you all - research nurses, clinical trial assistants, lab staff and co-investigators - for all of your continued efforts this year. I am very grateful for the work that everyone involved in the study has put in so far. In every meeting and newsletter we have to keep driving the message of minimising dropouts so we have a successful study, but **with one year of follow up left it's worth thinking about how successful we've been so far.**

We've had over 7000 patient visits, and we've centrifuged and stored over 70,000 aliquots of serum, plasma and urine. We've got a successful biological variability study currently submitted for publication. We've got a large cohort of UK ethnic minority patients. We've got just over 400 more iohexol visits to have, and then we'll be finished.

Hopefully all this will add up to a study that can improve clinical practice.

Thanks for helping us get this far, and please remember to pass on our thanks to all of our patients.



eGFR-C office closure: CRF completion table

Christmas 2018

The study office will be closed due to University of Birmingham closed days from Friday 21st December 2018 to Thursday 3rd January 2019.

In the event of any SAEs, please email r.ottridge@bham.ac.uk and follow the instructions on who to contact.

603 final CRFs have been returned, and overall we have an (excellent) average of 96% CRF return rate. Our leaders this month in promptly returning data are:

1. Derby - 100% of due CRFs returned
2. Leicester - 100%
3. Birmingham - 99%
4. East Kent - 99%
5. Salford - 94%
6. King's - 82%

Study Contact details

eGFR-C Chief Investigator

Dr Edmund Lamb
East Kent Hospitals
University NHS
Foundation Trust
elamb@nhs.net

Trial Manager

Ryan Ottridge
Birmingham Clinical Trials
Unit
eGFR-@trials.bham.ac.uk

Telephone

0121 415 9125

Fax

0121 415 9135

eGFR-C is funded by the National Institute for Health Research's Health Technology Assessment Programme and sponsored by the University of Birmingham and East Kent Hospitals University NHS Foundation Trust.

The views expressed in this newsletter are those of the authors and not necessarily those of the NIHR, NHS, or the Department of Health.

eGFR-C Newsletter

#19 December 2018

www.birmingham.ac.uk/eGFR-C



Study completion vs study drop out - December 2018

We need 1000+ completed iohexol tests at 36 months for 90% power. This means a maximum 15% dropout rate. Dropout means withdrawing, dying, or being lost to follow up. On the graphics below, as far as possible we need every site to have their green bar (patients completing) reach the black 85% line before their red bar (patients dropping out) does.

Some sites have passed the line or may do soon, but every iohexol test completed will make our results more reliable.

